Pricing
  1. US-listed companies
  2. Regenicin, Inc.
  3. Financials
  4. Stock-based compensation

Regenicin, Inc.【RGIN】

Market cap
$15.35K
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Sep 30, 20190-54.60%
Sep 30, 20160+109.78%
Sep 30, 20150+17.45%
Sep 30, 20140-97.79%
Sep 30, 20131+0.00%
Sep 30, 20121+43.90%
Sep 30, 20111

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)